Dr. Balkrishna Kale completed his Ph.D. in Organic Chemistry with a specialization in Catalysis at Daiichi-Sankyo-Jamia Hamdard University, New Delhi. His doctoral research focused on zinc metal-catalyzed C–C, C–N, and C–O bond formation, contributing significantly to the advancement of medicinal chemistry and sustainable synthetic methodologies. He also holds an M.Sc. in Organic Chemistry from the Department of Chemistry, Savitribai Phule Pune University, Pune.
Currently, Dr. Kale is a key leader at ARL Chemicals, where he oversees Business Development (BD). His primary research interests include peptide chemistry, transition metal catalysis, and energy storage chemicals, driving innovation and growth in these critical areas. With over 22 years of industrial research experience, Dr. Kale has held senior leadership roles at renowned organizations such as TCI Chemicals (as India Head - Quality Control), Daiichi Sankyo, Ranbaxy Research Laboratories, Torrent Research Centre and IPCA Laboratories. His expertise spans drug discovery research, API development, specialty chemicals, analytical development, and material science.
Dr. Kale has contributed to the discovery of several novel therapeutic targets, including JAK3, TYK2 inhibitors, NLRP3 inhibitors, FtsZ inhibitors, and IRAK-4 inhibitors. His credentials include product patents and publications in internationally peer-reviewed journals.
With his extensive experience, scientific expertise, and leadership acumen, Dr. Kale is dedicated to driving ARL Chemicals’ global expansion and advancing technological innovation.
Publications:
Patents:
